31 Jul 2026Open access
Initial HIV Therapy for Adults and Treatment-Associated Weight GainPublisher siteJAMA, HIV-related health complications and treatments
Active, last published 2026
In hiv/aids drug development and treatment
Simiso
Sokhela
Scholar“Research focused on HIV/AIDS drug development and treatment and adjacent fields.”
University of the Witwatersrand
South Africa17
H-index
1.8k
Citations
Simiso has not officially claimed their profile. If you are Simiso, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
imiso Sokhela is a researcher working on HIV/AIDS drug development and treatment. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Simiso's work has been cited 1,775 times across 3 active years. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
HIV/AIDS drug development and treatment×39HIV-related health complications and treatments×28HIV/AIDS Research and Interventions×26HIV Research and Treatment×17COVID-19 Clinical Research Studies×7
04 · Where I am
Affiliations
Affiliation on published researchUniversity of the Witwatersrand, South AfricaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
11 works1 Mar 2026Open access
Overcoming barriers, driving progress: Clinical science at IAS 2025Publisher siteJournal of the International AIDS Society, HIV/AIDS Research and Interventions
1 Feb 2026
Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialPublisher siteThe Lancet, HIV/AIDS drug development and treatment
4 Nov 2025Open access1cites
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trialPublisher siteNature Medicine
22 Nov 2024Open access
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in AfricaPublisher siteAIDS, SARS-CoV-2 and COVID-19 Research
11 Nov 2024Open access3cites
Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-outPublisher siteCurrent Opinion in HIV and AIDS, HIV/AIDS Research and Interventions
17 Sept 2024Open access3cites
<scp>DORA</scp>: 48‐week weight and metabolic changes in Black women with <scp>HIV</scp>, in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapyPublisher siteHIV Medicine, HIV-related health complications and treatments
16 Aug 202420cites
The long wait for long-acting HIV prevention and treatment formulationsPublisher siteThe Lancet HIV, HIV/AIDS Research and Interventions
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Simiso?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you